LRG1 contributes to the pathogenesis of multiple kidney diseases: a comprehensive review

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2024-04-03 DOI:10.1159/000538443

Chunyan Chen, Jingwei Zhang, Tao Yu, Haiya Feng, Jian Liao, Yifei Jia

{"title":"LRG1 contributes to the pathogenesis of multiple kidney diseases: a comprehensive review","authors":"Chunyan Chen, Jingwei Zhang, Tao Yu, Haiya Feng, Jian Liao, Yifei Jia","doi":"10.1159/000538443","DOIUrl":null,"url":null,"abstract":"Background: The increasing prevalence of kidney diseases has become a significant public health issue, with a global prevalence exceeding 10%. In order to accurately identify biochemical changes and treatment outcomes associated with kidney diseases, novel methods targeting specific genes have been discovered. Among these genes, leucine-rich α-2 glycoprotein 1 (LRG1) has been identified to function as a multifunctional pathogenic signaling molecule in multiple diseases, including kidney diseases. This study aims to provide a comprehensive overview of the current evidence regarding the roles of LRG1 in different types of kidney diseases. \nSummary: Based on a comprehensive review, it was found that LRG1 was up-regulated in the urine, serum, or renal tissues of patients or experimental animal models with multiple kidney diseases, such as diabetic nephropathy, kidney injury, IgA nephropathy, chronic kidney diseases (CKD), clear cell renal cell carcinoma (ccRCC), end-stage renal disease, canine leishmaniosis-induced kidney disease, kidney fibrosis, and aristolochic acid nephropathy. Mechanistically, the role of LRG1 in kidney diseases is believed to be detrimental, potentially through its regulation of various genes and signaling cascades, i.e. FN1, GPR56, VEGF, VEGFR-2, DR5, GDF15, HIF-1α, SPP1, ALK1-Smad1/5/8, NLRP3-IL-1b, and TGF-β pathway. \nKey Messages: Further research is needed to fully comprehend the molecular mechanisms by which LRG1 contributes to the pathogenesis and pathophysiology of kidney diseases. It is anticipated that targeted treatments focusing on LRG1 will be utilized in clinical trials and implemented in clinical practice in the future.","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538443","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The increasing prevalence of kidney diseases has become a significant public health issue, with a global prevalence exceeding 10%. In order to accurately identify biochemical changes and treatment outcomes associated with kidney diseases, novel methods targeting specific genes have been discovered. Among these genes, leucine-rich α-2 glycoprotein 1 (LRG1) has been identified to function as a multifunctional pathogenic signaling molecule in multiple diseases, including kidney diseases. This study aims to provide a comprehensive overview of the current evidence regarding the roles of LRG1 in different types of kidney diseases. Summary: Based on a comprehensive review, it was found that LRG1 was up-regulated in the urine, serum, or renal tissues of patients or experimental animal models with multiple kidney diseases, such as diabetic nephropathy, kidney injury, IgA nephropathy, chronic kidney diseases (CKD), clear cell renal cell carcinoma (ccRCC), end-stage renal disease, canine leishmaniosis-induced kidney disease, kidney fibrosis, and aristolochic acid nephropathy. Mechanistically, the role of LRG1 in kidney diseases is believed to be detrimental, potentially through its regulation of various genes and signaling cascades, i.e. FN1, GPR56, VEGF, VEGFR-2, DR5, GDF15, HIF-1α, SPP1, ALK1-Smad1/5/8, NLRP3-IL-1b, and TGF-β pathway. Key Messages: Further research is needed to fully comprehend the molecular mechanisms by which LRG1 contributes to the pathogenesis and pathophysiology of kidney diseases. It is anticipated that targeted treatments focusing on LRG1 will be utilized in clinical trials and implemented in clinical practice in the future.

查看原文本刊更多论文

LRG1 与多种肾脏疾病的发病机制有关：全面综述

背景：肾脏疾病的发病率越来越高，已成为一个重大的公共卫生问题，全球发病率超过 10%。为了准确鉴定与肾脏疾病相关的生化变化和治疗效果，人们发现了针对特定基因的新方法。在这些基因中，富亮氨酸α-2糖蛋白1（LRG1）已被确认在包括肾脏疾病在内的多种疾病中发挥多功能致病信号分子的作用。本研究旨在全面概述目前有关 LRG1 在不同类型肾脏疾病中作用的证据。摘要通过全面综述发现，LRG1在多种肾脏疾病患者或实验动物模型的尿液、血清或肾脏组织中上调，这些疾病包括糖尿病肾病、肾损伤、IgA肾病、慢性肾脏疾病（CKD）、透明细胞肾细胞癌（ccRCC）、终末期肾病、犬利什曼病诱导的肾病、肾纤维化和马兜铃酸肾病。从机理上讲，LRG1 在肾脏疾病中的作用被认为是有害的，可能是通过其对各种基因和信号级联（即 FN1、GPR56、VEGF、VEGFR-2、DR5、GDF15、HIF-1α、SPP1、ALK1-Smad1/5/8、NLRP3-IL-1b 和 TGF-β 通路）的调控。关键信息：要全面了解 LRG1 促成肾脏疾病发病机制和病理生理学的分子机制，还需要进一步的研究。预计针对 LRG1 的靶向治疗将被用于临床试验，并在未来应用于临床实践。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567